Cempra to Report Third Quarter 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Cempra to Report Third Quarter 2015 Financial Results

Baird Remains Bullish as Market Reacts to Cempra's (CEMP) 2nd Phase 3 Study of Solithromycin

October 19, 2015 10:17 AM EDT

Baird reiterated an Outperform rating and $38.00 price target on Cempra, Inc. (NASDAQ: CEMP) following the company's second Phase 3 study of solithromycin.

Analyst Brian Skorney commented, "While the market is clearly reacting to potential signals about safety, we believe that the second Phase 3 study of... More

Roth Capital Cuts Price Target on Cempra (CEMP) as Solithromycin Misses High Expectations

October 19, 2015 8:53 AM EDT

Roth Capital maintained a Buy rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $40.00 (from $56.00), after succumbing to high expectations for solithromycin. While solithromycin is expected to be approved for the treatment of CAP, lack of numerical superiority in older patients... More